CDEK
← All drugs Report issue

vinblastine

Trade name: velban

Small moleculeapproved

Approved

Nov 25, 1965

Vinblastine is a Vinca alkaloid obtained from the Madagascar periwinkle plant. Vinca alkaloids were found out in the 1950's by Canadian scientists, Robert Noble and Charles Beer for the first time. Medicinal applications of this plant lead to the monitoring of these compounds for their hypoglycemic activity, which is of little importance compared to their cytotoxic effects. They have been used to treat diabetes, high blood pressure and the drugs have even been used as disinfectants. Nevertheless, the vinca alkaloids are so important for being cancer fighters. The mechanism of action of vinblastine sulfate has been related to the inhibition of microtubule formation in the mitotic spindle, resulting in an arrest of dividing cells at the metaphase stage. Vinblastine is an antineoplastic agent used to treat Hodgkin's disease, non-Hodgkin's lymphomas, mycosis fungoides, cancer of the testis, Kaposi's sarcoma, Letterer-Siwe disease, as well as other cancers. — NCATS

Clinical trial activity

207 trials · 218 clinical orgs · 7 marketing orgs

Phase 1
23
Phase 2
175
Phase 3
64
Phase 4
4

Earliest trial started Apr 1, 1989 (NCT00002715)

Timeline

1960s

  1. Nov 25, 1965

    Eli Lilly — Earliest FDA Approval

  2. Nov 25, 1965

    Eli Lilly — NDA Organization

1980s

  1. Apr 9, 1987

    West-Ward Pharmaceutical — Marketing Organization

  2. Apr 9, 1987

    Hikma — Marketing Organization

  3. Apr 29, 1987

    Fresenius — Marketing Organization

  4. Aug 18, 1987

    Hospira — Marketing Organization

  5. Jan 1, 1989

    Earliest Phase 2 Sponsor(trial)

  6. Jan 1, 1989

    Earliest Phase 3 Sponsor(trial)

1990s

  1. Jan 1, 1995

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewNov 25, 1965

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
Mol. weight
810.99 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 29060-le
  • 29060-le
  • [3h]-vinblastine
  • [3h]-vinblastine
  • int230-6
  • velban
  • velban
  • velban
  • velban
  • velbe
  • velbe
  • vinblastin
  • vinblastin
  • vinblastin
  • vinblastina
  • vinblastina
  • vinblastine
  • vinblastine
  • vinblastine
  • vinblastine
  • vinblastine
  • vinblastine
  • vinblastine
  • vinblastine
  • vinblastine
  • vinblastine
  • vinblastine sulfate
  • vinblastine sulfate
  • vinblastine sulfate
  • vinblastine sulfate
  • vinblastine sulphate
  • vinblastine sulphate
  • vinblastinum
  • vinblastinum
  • vinblast,lederle
  • vincaleucoblastin
  • vincaleucoblastine
  • vincaleucoblastine
  • vincaleukoblastine
  • vincaleukoblastine
  • vincaleukoblastine

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07013565Phase 2Aug 7, 2025Medical College of Wisconsin, Memorial Sloan-Kettering Cancer Center, Michigan State University, New York Medical College, Ohio State University, University of Alabama, Birmingham, University of California, Irvine, University of North Carolina at Chapel Hill, University of Pennsylvania, University of Utah
NCT06745076Phase 2Jun 1, 2025University of Washington
NCT06960577Phase 3May 15, 2025AstraZeneca
NCT06984146Phase 2Apr 15, 2025Government of Russia
NCT06358573Phase 2Oct 24, 2024Cantonal Hospital of St. Gallen, Cantonal Hospital Winterthur, Swiss Group for Clinical Cancer Research
NCT06848569Phase 2Oct 23, 2024Sun Yat-Sen University
NCT06831370Phase 4Aug 28, 2024Takeda
NCT06263231Phase 3Jun 28, 2024Intensity Therapeutics, Johns Hopkins University, Premier Research Group
NCT06377566Phase 2Apr 17, 2024Memorial Sloan-Kettering Cancer Center, Seattle Genetics
NCT06204614Early Phase 1 (Phase 1)Feb 14, 2024Harvard University
NCT06164275Phase 2Dec 31, 2023National Cancer Institute (NCI), Northwestern University
NCT05776758Phase 3Nov 30, 2023ISTITUTO REGINA ELENA
NCT05949931Phase 2Aug 31, 2023Sun Yat-Sen University
NCT05675410Phase 3May 11, 2023National Cancer Institute (NCI), State University of New York, Buffalo
NCT07171827N/AMar 1, 2023Helwan University
NCT05404945Phase 2Jul 26, 2022Merck, University of Virginia
NCT05180825Phase 2May 5, 2022University of Strasbourg
NCT05253495Phase 2Feb 1, 2022New York Medical College
NCT04685616Phase 3Nov 30, 2021Canadian Cancer Trials Group, Takeda, University of London, University of Manchester
NCT05137262Phase 2Oct 13, 2021AstraZeneca, University of Texas at Houston
Showing 20 of 207 trials
Page 1 / 11

Organizations

Research & Development (218)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government511841989
University of Texas at HoustonAcademic/Hospital131131995
European Organisation for Research and Treatment of CancerAcademic/Hospital121121989
Cornell UniversityAcademic/Hospital10641996
University of CologneAcademic/Hospital101031998
Eastern Cooperative Oncology GroupAcademic/Hospital9421994
Seattle GeneticsFor profit9252010
Southwest Oncology GroupAcademic/Hospital9621992
Stanford UniversityAcademic/Hospital9531989
Institut Gustave RoussyAcademic/Hospital8431994
St. Jude Children's HospitalAcademic/Hospital8721997
University of TorontoAcademic/Hospital8431997
Canadian Cancer Trials GroupAcademic/Hospital6221994
Cancer and Leukemia Group B (CALGB)Academic/Hospital6011992
Fondazione Italiana Diabete OnlusAcademic/Hospital6522003
Harvard UniversityAcademic/Hospital6432000
MerckFor profit6212017
University of WashingtonAcademic/Hospital6321992
AstraZenecaFor profit5122014
Baylor UniversityAcademic/Hospital5231997
218 organizations
Page 1 / 11

Marketing (9)

OrganizationOrg typeRelationshipDate
AbraxisFor profitMKTG—
Athenex, Inc.For profitMKTG—
Eli LillyFor profitSYNNov 25, 1965
Eli LillyFor profitNDANov 25, 1965
FreseniusFor profitMKTGApr 29, 1987
HikmaFor profitSYNApr 9, 1987
HikmaFor profitMKTGApr 9, 1987
HospiraFor profitMKTGAug 18, 1987
West-Ward PharmaceuticalFor profitMKTGApr 9, 1987